High Efficiency Drug Repurposing Design for New Antifungal Agents

• Published in: Methods and protocols Vol. 2; no. 2; p. 31
• Main Authors: Kim, Jong H, Chan, Kathleen L, Cheng, Luisa W, Tell, Lisa A, Byrne, Barbara A, Clothier, Kristin, Land, Kirkwood M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 17-04-2019; MDPI AG
• Subjects: antifungal intervention; antioxidant system; Aspergillus; chemosensitization; Communication; drug repurposing; drug resistance; mutants; pathogen control; Aspergillus; drug repurposing; pathogen control; antioxidant system; mutants; chemosensitization; drug resistance; antifungal intervention
• ISSN: 2409-9279; 2409-9279
• DOI: 10.3390/mps2020031

Current antifungal interventions have often limited efficiency in treating fungal pathogens, particularly those resistant to commercial drugs or fungicides. Antifungal drug repurposing is an alternative intervention strategy, whereby new utility of various marketed, non-antifungal drugs could be repositioned as novel antifungal agents. In this study, we investigated "chemosensitization" as a method to improve the efficiency of antifungal drug repurposing, wherein combined application of a second compound (viz., chemosensitizer) with a conventional, non-antifungal drug could greatly enhance the antifungal activity of the co-applied drug. Redox-active natural compounds or structural derivatives, such as thymol (2-isopropyl-5-methylphenol), 4-isopropyl-3-methylphenol, or 3,5-dimethoxybenzaldehyde, could serve as potent chemosensitizers to enhance antifungal activity of the repurposed drug bithionol. Of note, inclusion of fungal mutants, such as antioxidant mutants, could also facilitate drug repurposing efficiency, which is reflected in the enhancement of antifungal efficacy of bithionol. Bithionol overcame antifungal (viz., fludioxonil) tolerance of the antioxidant mutants of the human/animal pathogen
. Altogether, our strategy can lead to the development of a high efficiency drug repurposing design, which enhances the susceptibility of pathogens to drugs, reduces time and costs for new antifungal development, and abates drug or fungicide resistance.